AnHorn Medicines
AnHorn Medicines is a novel drug discovery company focused on developing therapies that target and degrade disease-related proteins. Their proprietary BIGPRO® platform utilizes Targeted Protein Degradation (TPD) to create innovative drugs for cancer, neurodegeneration, and age-related diseases. With a strong pipeline and an AI-enabled platform called AIMCADD®, AnHorn aims to address difficult-to-treat diseases and those with drug resistance. The company has achieved significant milestones, including IND clearance for its lead product AH-001, and is actively seeking partnerships to expand its impact in the pharmaceutical industry.
AnHorn Medicines
AnHorn Medicines is a novel drug discovery company focused on developing therapies that target and degrade disease-related proteins. Their proprietary BIGPRO® platform utilizes Targeted Protein Degradation (TPD) to create innovative drugs for cancer, neurodegeneration, and age-related diseases. With a strong pipeline and an AI-enabled platform called AIMCADD®, AnHorn aims to address difficult-to-treat diseases and those with drug resistance. The company has achieved significant milestones, including IND clearance for its lead product AH-001, and is actively seeking partnerships to expand its impact in the pharmaceutical industry.